Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Soft Tissue Sarcoma
Conditions
Soft Tissue Sarcoma
Trial Timeline
Mar 10, 2011 → Aug 10, 2016
NCT ID
NCT01327885About Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV is a phase 3 stage product being developed by Eisai for Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01327885. Target conditions include Soft Tissue Sarcoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01327885 | Phase 3 | Completed |
Competing Products
20 competing products in Soft Tissue Sarcoma